Drugs.com - New Drug Approvals

Arcutis’ Zoryve (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older

WESTLAKE VILLAGE, Calif., May 22, 2025 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the U.S...

May 27, 2025 - 02:50
 0
Arcutis’ Zoryve (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older
WESTLAKE VILLAGE, Calif., May 22, 2025 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the U.S...
Read More

Tags:

Previous Article

Celltrion's Yuflyma (adalimumab-aaty) Receives FDA Interchangeability Designatio...

Next Article

Fortescue seeks EPBC Act approval for 644MW solar PV plant in Western Australia

Related Posts

FDA Grants Accelerated Approval to Avmapki Fakzynja Co-Pack (avutometinib capsules/defactinib tablets) for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer

FDA Grants Accelerated Approval to Avmapki Fakzynja Co-...

May 13, 2025  0

Mirum’s Livmarli Now FDA Approved in Tablet Formulation

May 12, 2025  0

Theratechnologies Receives FDA Approval for Egrifta WR ...

May 12, 2025  0